We concluded that if the loss of CD20, be it induced by CRISPR/Cas9 KO or after RTX therapy, is accompanied by an increased PC differentiation, then we should identify PC-specific genes after RTX therapy of B cell malignancies in vivo. Here, MS4A1 is linked to pachyonychia congenita.